EMA Recommends Granting a Marketing Authorisation for Lisocabtagene Maraleucel
It is indicated for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma and follicular lymphoma grade 3B, after two or more lines of systemic therapy